Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study

doi:10.1093/rheumatology/kead707

科研成果详情

题名	Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study
作者	Lin, Sishi1,2; Zhang, Ji1,2; You, Xiaohan1,2; Chen, Bo 1,2; Liang, Yan1,2; Zhou, Yin1,2; Ding, Xiaokai1,2; Lv, Yinqiu1,2; Zhang, Huidi1,2; Su, Bofeng1,2; Bai, Yongheng3; Chen, Chaosheng1,2,4
发表日期	2023-12-25
发表期刊	RHEUMATOLOGY 影响因子和分区
语种	英语
原始文献类型	Article ; Early Access ; Journal Article
关键词	belimumab lupus nephritis efficacy safety Belimumab Efficacy Lupus nephritis Safety
其他关键词	EULAR/ERA-EDTA RECOMMENDATIONS ; ASSOCIATION-EUROPEAN DIALYSIS ; MANAGEMENT ; RHEUMATISM ; LEAGUE
摘要	Objectives: To evaluate the differences in efficacy and safety between lupus nephritis (LN) patients who received belimumab plus standard therapy and those who received only standard therapy in real world practice. Methods: Patients diagnosed with LN at the First Affiliated Hospital of Wenzhou Medical University from November 2012 to July 2023 were identified, and eligible cases were divided into two groups according to whether they received additional treatment with belimumab during the course of the disease. Results: A total of 1169 LN patients were identified from our follow-up database. In total, 112 patients receiving add-on treatment with belimumab (BLM group) and 112 control patients matched for relevant baseline characteristics were enrolled in this study. The median duration of treatment with belimumab was 13.82 [7.24, 20.29] months. Compared with the control group, the BLM group had more significant improvement in disease activity indicators such as serum albumin and complement levels, significantly lower B-cell count, immunoglobulin, and earlier first attainment of renal remission, but there was no significant improvement in renal function and kidney-related events or death during the 2-year follow-up period. In the BLM group, the treatment effect of belimumab was more prominent in patients with lower levels of proteinuria. The safety profile of belimumab treatment was favorable, with a lower incidence of respiratory tract infection in the BLM group than in the control group during the follow-up period (P = 0.015). Conclusions: This real-world study revealed that add-on treatment with belimumab provided better disease remission, and the therapeutic effect was more significant in patients with lower proteinuria levels. In addition, it had a favorable safety profile and reduced the risk of respiratory tract infection. [Graphics]
资助项目	Natural Science Foundation of Zhejiang Province [LY22H050004]
出版者	OXFORD UNIV PRESS
ISSN	1462-0324
EISSN	1462-0332
DOI	10.1093/rheumatology/kead707
页数	9
WOS类目	Rheumatology
WOS研究方向	Rheumatology
WOS记录号	WOS:001169770000001
收录类别	SCIE ; PUBMED
在线发表日期	2023-12
URL	查看原文
PubMed ID	38145498
通讯作者地址	[Chen, Chaosheng]Wenzhou Med Univ, Dept Nephrol, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
TOP期刊	TOP期刊
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/209956
专题	附属第一医院_肾内科温州医科大学第一临床医学院（信息与工程学院）、附属第一医院_浙江省胰脏肝脏危重性疾病重点实验室
通讯作者	Chen, Chaosheng
作者单位	1.Wenzhou Med Univ, Affiliated Hosp 1, Dept Nephrol, Wenzhou, Zhejiang, Peoples R China; 2.Wenzhou Med Univ, Inst Chron Kidney Dis, Wenzhou, Zhejiang, Peoples R China; 3.Wenzhou Med Univ, Key Lab Diag & Treatment Severe Hepatopancreat Dis, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; 4.Wenzhou Med Univ, Dept Nephrol, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China
第一作者单位	附属第一医院_肾内科; 温州医科大学
通讯作者单位	附属第一医院_肾内科
第一作者的第一单位	附属第一医院_肾内科
推荐引用方式 GB/T 7714	Lin, Sishi,Zhang, Ji,You, Xiaohan,et al. Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study[J]. RHEUMATOLOGY,2023.
APA	Lin, Sishi., Zhang, Ji., You, Xiaohan., Chen, Bo., Liang, Yan., ... & Chen, Chaosheng. (2023). Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study. RHEUMATOLOGY.
MLA	Lin, Sishi,et al."Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study".RHEUMATOLOGY (2023).